Cellay

Cellay is a private, early-stage biotech firm pioneering a novel oligonucleotide-based FISH probe technology that enables same-day chromosomal enumeration with a hybridization time of only 5-10 minutes at room temperature. Operating in the diagnostics and cell therapy sectors, the company leverages a cGMP manufacturing process to produce its proprietary probes, which are currently marketed as Analyte Specific Reagents (ASRs) for research use. While not yet FDA-approved for clinical diagnostics, the technology presents a significant potential to streamline workflows in cytogenetics labs, pre-implantation genetic testing, and cell therapy quality control. The company's growth is tied to expanding the adoption of its rapid FISH platform and navigating the regulatory pathway for clinical use.

Proprietary oligonucleotide-based FISH probe platform enabling rapid (5-10 minute), isothermal hybridization for chromosomal enumeration and analysis.

Cellay competes with large, diversified diagnostics companies like Abbott and Agilent that offer traditional BAC-based FISH probes, as well as other cytogenetics tools providers. Its primary competitive edge is speed and simplicity, but it faces challenges in displacing entrenched, validated technologies and scaling commercial reach against well-resourced incumbents.